Abstract:Objective To study the efficacy of EOF neoadjuvant chemotherapy combined with total laparoscopic D2 radical surgery on locally advanced gastric cancer and the expression of sE-cad and TRAF6. Methods A total of 120 patients with locally advanced gastric cancer admitted to our hospital from August 2011 to November 2012 were enrolled and divided into EOF neoadjuvant chemotherapy + total laparoscopic D2 radical surgery group (observation group) and total laparoscopic D2 radical surgery (control group) according to the random digital table method (60 cases in each group). Short term and long term Survival data, serum soluble sE-cad and TRAF6 were monitored and compared in both gourp. Results ① There were no differences in gender, age, BMI, tumor location and diameter, tumor pathology, and UICC staging (P?>?0.05). ② The total effective rate and the tumor control rate of the observation group weres higher than the control group. The difference was statistically significant (P?0.05); ③ Comparison of adverse reactions: The incidence of adverse reactions in the control group and control group were 53.3% and 58.3%, respectively, and the difference was not statistically significant (P?>?0.05). ④ After treatment, the serum levels of sE-cad and TRAF6 were lower in both groups than those before treatment. Additionally, they were detected with a lower level in the observation group. The difference was statistically significant (P?0.05) ⑤ Follow-up and prognosis: the shortest follow-up of 88 patients was 58 days, the longest was 1780 days, and the median survival time was 682 days. As of December 2017, 5 patients were lost to follow-up ,32 died and 23 cases survived in observation group. In the control group, 7 cases were lost to follow-up, 39 cases died and 14 cases survived. The difference in survival rate was statistically significant (P?0.05). Conclusions EOF chemotherapy plus total laparoscopic D2 radical surgery can effectively improve the prognosis of patients with D2 radical resection, and can effectively reduce the levels of sE-cad and TRAF6, reduce the invasiveness of tumors and improve the prognosis of patients. It is worthy of clinical application.